Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mouret

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Long term improved quality of life by a 2-week group physical and educational intervention shortly after breast cancer chemotherapy completion. Results of the 'Programme of Accompanying women after breast Cancer treatment completion in Thermal resorts' (PACThe) randomised clinical trial of 251 patientsF Kwiatkowski, M A Mouret-Reynier, M Duclos, et al.
ESMO Open|June 20, 2022
Factors associated with enrolment in clinical trials among women with early-stage breast cancerD Presti, J Havas, D Soldato, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancerA Gonçalves, J-Y Pierga, J-M Ferrero, et al.
ESMO Open|February 13, 2024
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomesM A Franzoi, M Aupomerol, J Havas, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
International Journal of Cancer|December 10, 2015
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancerJ M Nabholtz, N Chalabi, N Radosevic-Robin, et al.
ESMO Open|April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialM Saint-Ghislain, S Chabaud, F Dalenc, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosisT Gaillard, M Carton, A Mailliez, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Long term improved quality of life by a 2-week group physical and educational intervention shortly after breast cancer chemotherapy completion. Results of the 'Programme of Accompanying women after breast Cancer treatment completion in Thermal resorts' (PACThe) randomised clinical trial of 251 patientsF Kwiatkowski, M A Mouret-Reynier, M Duclos, et al.
ESMO Open|June 20, 2022
Factors associated with enrolment in clinical trials among women with early-stage breast cancerD Presti, J Havas, D Soldato, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancerA Gonçalves, J-Y Pierga, J-M Ferrero, et al.
ESMO Open|February 13, 2024
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomesM A Franzoi, M Aupomerol, J Havas, et al.
ESMO Open|July 25, 2021
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)D Dano, A Lardy-Cleaud, A Monneur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
International Journal of Cancer|December 10, 2015
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancerJ M Nabholtz, N Chalabi, N Radosevic-Robin, et al.
ESMO Open|April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trialM Saint-Ghislain, S Chabaud, F Dalenc, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosisT Gaillard, M Carton, A Mailliez, et al.
Pageof 6